Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock Has Average Target Price of $6.75

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $7.50.

ZNTL has been the topic of several research analyst reports. Rodman & Renshaw initiated coverage on Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They issued a “buy” rating and a $11.00 price objective on the stock. William Blair assumed coverage on Zentalis Pharmaceuticals in a report on Wednesday, September 16th. They set an “outperform” rating for the company. Mizuho assumed coverage on Zentalis Pharmaceuticals in a research report on Friday, July 17th. They issued an “outperform” rating and a $8.00 target price for the company. Wall Street Zen lowered shares of Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Friday, October 2nd.

Zentalis Pharmaceuticals Stock Performance

Zentalis Pharmaceuticals stock opened at $2.55 on Monday. The company has a market capitalization of $182.76 million, a PE ratio of -1.31 and a beta of 1.93. Zentalis Pharmaceuticals has a fifty-two week low of $1.21 and a fifty-two week high of $6.95. The firm has a 50 day moving average price of $3.63 and a 200 day moving average price of $3.87.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). As a group, equities research analysts forecast that Zentalis Pharmaceuticals will post -2.11 earnings per share for the current year.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, major shareholder Group Walters bought 4,335,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were purchased at an average cost of $3.50 per share, with a total value of $15,172,500.00. Following the purchase, the insider directly owned 17,844,973 shares in the company, valued at approximately $62,457,405.50. This represents a 32.09% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZNTL. CTC Alternative Strategies Ltd. purchased a new position in shares of Zentalis Pharmaceuticals in the 1st quarter valued at $29,000. Spark Investment Management LLC purchased a new stake in Zentalis Pharmaceuticals in the second quarter valued at $61,000. The Manufacturers Life Insurance Company purchased a new stake in Zentalis Pharmaceuticals in the second quarter valued at $69,000. State of Wyoming acquired a new position in Zentalis Pharmaceuticals in the second quarter valued at $91,000. Finally, Sivia Capital Partners LLC acquired a new position in Zentalis Pharmaceuticals in the fourth quarter valued at $27,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc (NASDAQ: ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research programs are designed to target biological pathways involved in tumor growth, survival and resistance to existing therapies.

Zentalis’ lead investigational product is azenosertib, also known as ZN-c3, an oral WEE1 inhibitor being evaluated in clinical trials for several advanced cancers.